Skip to main content
. 2024 Jan 24;15:1288362. doi: 10.3389/fphar.2024.1288362

FIGURE 2.

FIGURE 2

Distribution statistics of adverse events (AEs) based on PTs’ and SOCs’ classification in monotherapy. (A) Pie chart visualizing the number of AEs reported at high frequency for the seven HER2 inhibitors. (B) Mulberry diagram visualizing the correspondence of adverse events (soc_name) and outcomes (OUTC_COD) reported in cases treated with T-DXd and trastuzumab. (C) Heat map displays the distribution of AEs reporting rates of gastrointestinal disorders for seven HER2 inhibitors.